新辅助化疗加上卡梅利祖马布治疗局部晚期宫癌 (NACI研究):多中心,单臂,第二阶段试验
Kezhen Li1, Jing Chen1, Yingjie Hu1
1Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center, Key Laboratory of the Ministry of Education, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
新辅助化疗免疫疗法在治疗局部晚期宫癌方面表现出高效,具有98%的客观反应率和可控的副作用. 这种方法与手术相结合,显示出作为一种新的治疗策略的希望.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 局部晚期宫癌的预后不好,治疗选择有限.
- 新辅助免疫疗法提供了一种改善结果的潜在策略.
- 这项研究调查了新辅助化学免疫疗法对于这个患者群体.
研究的目的:
- 评估新辅助化疗免疫治疗在局部晚期宫癌患者的疗效和安全性.
- 确定客观响应率 (ORR) 作为主要终点.
- 评估新辅助疗法的安全性.
主要方法:
- 在中国的8家三级医院进行了单臂二期试验.
- 招募的患者年龄为18-70岁,患有未经治疗的局部晚期子宫癌 (FIGO 2018 阶段IB3,IIA2,IIB/IIIC1r,瘤直径≥4厘米) 和ECOG PS 0-1.
- 治疗包括一轮西斯/纳布-帕克利塔塞尔,然后两轮西斯/纳布-帕克利塔塞尔加上卡梅利祖马布,随后根据反应进行手术或化疗放射治疗.
主要成果:
- 85名患者接受治疗,随访时间中位数为11.0个月.
- 客观反应率为98% (19%的完整反应,79%的部分反应) 被观察到.
- 最常见的3-4级不良事件包括淋巴衰竭 (25%),中性衰竭 (12%),白血病 (8%);没有发生严重不良事件或与治疗相关的死亡.
结论:
- 新辅助化疗免疫疗法在局部发达的宫癌中表现出有前途的抗瘤活性.
- 治疗方案与可管理的不良事件概况相关.
- 将新辅助化学免疫疗法与激进手术相结合,代表了一种潜在的新型治疗方法.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
